Axogen completes submission of biologics license application to u.s. food and drug administration for avance nerve graft®

Alachua, fla. and tampa, fla., sept. 06, 2024 (globe newswire) -- axogen, inc. (nasdaq: axgn), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its biologics license application (bla) to the u.s. food and drug administration (fda) for avance nerve graft®.
AXGN Ratings Summary
Quant
AXGN Quant Ranking
Sector
Industry
Quant Rating
Quant Score